The nonchalance of Carl Icahn in his Tuesday evening CNBC interview, as he was handed and then proceeded to sip on a martini, was of no solace to investors in Wednesday’s trading session, as
Markets were up across the board with all the major indices reporting gains on a slew of better-than-expected earnings reports from several key players, as well as some other major positive
Stocks declined again Friday on choppy action. After opening down and appearing to continue the rapid declines of yesterday, the major indices bounced back in morning trading, with the S&P 500
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
| Website: | www.aldeyra.com |
| Email: | ALDX@investorrelations.com |
| Main Phone: | +1 781 761-4904 |
| Address: | 131 Hartwell Avenue |
| Address 2: | Suite 320 |
| State: | MA |
| City / Town: | Lexington |
| Country: | US |
| Postal Code: | 02421 |
| Exchange: | NSC |
| CEO: | Todd C. Brady |
| Employees: | 11 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The nonchalance of Carl Icahn in his Tuesday evening CNBC interview, as he was handed and then proceeded to sip on a martini, was of no solace to investors in Wednesday’s trading session, as
Markets were up across the board with all the major indices reporting gains on a slew of better-than-expected earnings reports from several key players, as well as some other major positive
Stocks declined again Friday on choppy action. After opening down and appearing to continue the rapid declines of yesterday, the major indices bounced back in morning trading, with the S&P 500
Aldeyra Therapeutics ($ALDX) is a biotechnology company focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be
The full IPO calendar is available at IPOpremium. Scheduled IPOs are ranked by IPO size. Almost $5 billion in scheduled new offerings. (1) Based in Detroit, MI, Ally Financial ($ALLY) scheduled a
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
